GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

117 calculators match

GastroAGI flagship

1
MASLD–MASH NITIntegrated non-invasive assessment of MASLD fibrosis and at-risk MASH — FIB-4, APRI, NFS, FAST, Agile 3+, Agile 4, ELF and ADAPT in one pass

Most used

21
MELD-NaAssesses the severity of chronic liver diseaseChild-Pugh ScoreAssesses the prognosis of chronic liver disease, mainly cirrhosisFIB-4 IndexLiver fibrosis scoring indexAPRIAST to platelet ratio — liver fibrosisMaddrey's DFAlcoholic hepatitis severityGlasgow-BlatchfordUpper GI bleed risk stratificationGAHSGlasgow alcoholic hepatitis scoreMontreal IBDIBD classification — CD & UCMayo ScoreUlcerative colitis activityBISAP ScoreBedside index for severity of pancreatitisCLIF-SOFAOrgan failure scoring in cirrhosisAlcohol ContentStandard drinks & alcohol grams calculatorAARC-ACLFAcute-on-chronic liver failure gradePELD / CR ScorePediatric end-stage liver diseaseHarvey-BradshawCrohn's disease activity indexCTSICT severity index — pancreatitisRockall ScoreGI bleed rebleeding & mortality riskCAGEAlcohol use disorder screening (4 questions)MELD 3.0Updated MELD — sex-inclusive formulaAUDIT ScoreAlcohol use disorders identification testVOCAL-Penn ScorePost-operative mortality risk in cirrhosis surgery

Liver & Cirrhosis

17
ALBI GradeAlbumin-bilirubin liver function grade in HCCUKELD ScoreUK model for end-stage liver diseaseMELD-XIMELD excluding INR — for anticoagulated patientsWest Haven CriteriaHepatic encephalopathy gradingMilan CriteriaLiver transplant eligibility in hepatocellular carcinomaLI-RADS v2018 (CT/MRI)Liver observation category from size, APHE and major featuresBCLC StagingHepatocellular carcinoma stage and treatment allocationSimplified AIH CriteriaSimplified criteria for autoimmune hepatitisRevised Original AIH ScoreIAIHG 1999 comprehensive autoimmune hepatitis scoreSAAGSerum-ascites albumin gradient — cause of ascitesR FactorHepatocellular vs cholestatic pattern in liver injuryCLIF-C ACLFMortality prediction in acute-on-chronic liver failureKing's College CriteriaTransplant criteria in acute liver failureGALAD ScoreHCC detection from gender, age, AFP-L3, AFP and DCPMetroticket 2.0AFP-adjusted up-to-seven for HCC transplant eligibilityRUCAMCausality in drug- and herb-induced liver injuryBaveno VII CriteriacACLD, CSPH and sparing screening endoscopy

Fibrosis & MASLD

8
NAFLD Fibrosis ScoreAdvanced fibrosis probability in MASLD/NAFLDBARD ScoreBMI, AST/ALT ratio, diabetes — MASLD fibrosisFatty Liver IndexPredicts hepatic steatosis from routine labsFibrotic NASH Index (FNI)At-risk NASH probability from AST, HbA1c and HDLNAFLD Activity Score (NAS)Histologic activity grade — steatosis, inflammation, ballooningMEFIB IndexMRE + FIB-4 rule for significant fibrosis (≥F2) in MASLDFAST ScoreFibroScan-AST — at-risk NASH from LSM, CAP and ASTSAFE ScoreSteatosis-Associated Fibrosis Estimator for MASLD in primary care

Pancreas & Biliary

8
Ranson's CriteriaAcute pancreatitis severity at 48 hoursGlasgow-Imrie CriteriaAcute pancreatitis severity — the PANCREAS criteriaHAPSHarmless acute pancreatitis scoreTokyo Guidelines — CholangitisTG18 diagnosis and severity grade for acute cholangitisTokyo Guidelines — CholecystitisTG18 diagnosis and severity grade for acute cholecystitisBiliary Pain (Rome IV)Rome IV — defining biliary-type pain before interventionFunctional Pancreatic SODRome IV — pancreatic sphincter of Oddi disorderRevised Atlanta ClassificationAcute pancreatitis severity — mild, moderately severe, severe

IBD

9
Truelove & Witts CriteriaAcute severe ulcerative colitis — admission decisionUCEISUlcerative colitis endoscopic index of severitySCCAISimple clinical colitis activity index — symptoms onlyCDAICrohn's disease activity index — the trial standardSES-CDEndoscopic severity in Crohn's diseasePUCAIPaediatric ulcerative colitis activity indexTravis (Oxford) CriteriaDay 3 colectomy risk in acute severe ulcerative colitisHo IndexDay 3 steroid failure risk in acute severe ulcerative colitisRutgeerts ScorePostoperative Crohn's recurrence at ileocolonoscopy

GI Bleeding

7
EVendo ScorePredicts oesophageal varices needing treatmentForrest ClassificationPeptic ulcer bleeding — rebleeding risk at endoscopyAIMS65 ScoreUpper GI bleed mortality — five bedside criteriaOakland ScoreSafe-discharge risk for acute lower GI bleedingABC ScoreAge, blood tests, comorbidities — GI bleed mortalitySarin ClassificationEndoscopic classification of gastric varicesEGUS (Gastric Ulcer)Malignancy risk in a gastric ulcer, and who needs repeat endoscopy

Alcohol

2
ABIC ScoreAge, bilirubin, INR, creatinine — alcoholic hepatitisLille ModelSteroid response at day 7 in alcoholic hepatitis

Upper GI

4
Chicago Classification v4.0Oesophageal motility pattern from high-resolution manometryLA Classification (Oesophagitis)Los Angeles grade A–D for erosive oesophagitisPrague C & M CriteriaCircumferential and maximal extent of Barrett's oesophagusEREFS (Eosinophilic Oesophagitis)Endoscopic reference score — oedema, rings, exudates, furrows, stricture

Colorectal

3
Boston Bowel Prep ScaleColonoscopy preparation adequacy by segmentStool Osmotic GapOsmotic vs secretory diarrhoea from stool electrolytesATLAS Score (C. difficile)Predicted response to therapy in Clostridioides difficile infection

Functional GI

37
Bristol Stool ScaleStool form types 1–7 and colonic transitRome IV Criteria for IBSIrritable bowel syndrome diagnosis and subtypeFunctional ConstipationRome IV — two of six items, IBS excludedOpioid-Induced ConstipationRome IV — constipation tied to opioid therapyFunctional DiarrhoeaRome IV — loose stools without predominant painFunctional Bloating / DistensionRome IV — bloating without other bowel disorder criteriaUnspecified Functional Bowel DisorderRome IV — bowel symptoms fitting no other categoryCentrally Mediated Abdominal Pain (CAPS)Rome IV — continuous pain unrelated to gut eventsNarcotic Bowel SyndromeRome IV — opioid-induced hyperalgesia of the gutFaecal Incontinence (Rome IV)Rome IV — the criteria, and why nobody is askedFunctional Anorectal PainLevator ani, unspecified pain and proctalgia fugaxFunctional Defecation DisordersRome IV — dyssynergia and inadequate propulsionInfant RegurgitationRome IV — the happy spitter, and the alarm features that rule it outInfant ColicRome IV — recurrent unexplained crying in a well infant under 5 monthsInfant DyscheziaRome IV — straining before a soft stool, and why not to intervenePaediatric Functional ConstipationRome IV — two of six over one month, with overflow soiling as a criterionToddler's DiarrhoeaRome IV functional diarrhoea of childhood — painless, thriving childPaediatric Cyclic Vomiting SyndromeRome IV — both age bands, with different criteria for eachPaediatric Rumination SyndromeRome IV — infant and child/adolescent criteriaFunctional Nausea & Vomiting (Children)Rome IV — two separate disorders that can be met togetherAerophagiaRome IV — distension that increases through the dayPaediatric Functional DyspepsiaRome IV — four times a month, with PDS and EPS subtypingPaediatric Irritable Bowel SyndromeRome IV — plus the constipation clause clinicians missAbdominal MigraineRome IV — stereotypical incapacitating episodes weeks apartFunctional Abdominal Pain — NOSRome IV — the residual category, reached after the other threeNonretentive Faecal IncontinenceRome IV — soiling without retention, where laxatives make it worseFunctional DyspepsiaRome IV — with PDS and EPS subtypingRumination SyndromeRome IV — effortless regurgitation without retchingCyclic Vomiting SyndromeRome IV — stereotypical episodic vomitingCannabinoid HyperemesisRome IV — CVS pattern relieved by cannabis cessationChronic Nausea & VomitingRome IV — chronic nausea and vomiting syndromeBelching DisordersRome IV — supragastric vs gastric belchingFunctional HeartburnRome IV — heartburn with normal acid exposureReflux HypersensitivityRome IV — normal acid exposure, positive symptom associationFunctional Chest PainRome IV — non-cardiac, non-reflux chest painGlobusRome IV — painless lump-in-throat sensationFunctional DysphagiaRome IV — dysphagia with normal endoscopy and manometry
  1. Calculators
  2. /
  3. CLIF-SOFA
Liver & CirrhosisMost used

CLIF-SOFA

Organ failure scoring in cirrhosis

Organ systems

Liver: 0 below 1.2, 1 to 2, 2 to 6, 3 to 12, 4 above 12 mg/dL.

Kidney: an organ failure at 2.0 mg/dL and above, which is a lower bar than the other systems.

Coagulation: 0 below 1.1, rising to 4 at 2.5 and above.

Circulation: 0 at 70 or above, 1 below 70. Vasopressor use overrides this to 3.

West Haven grade, scored directly. Grade 3 or above counts as cerebral failure.

Respiratory

Enter one ratio, or neither if no oxygenation data is available. Mechanical ventilation alone scores 3.

Preferred when an arterial blood gas is available.

Used only when PaO₂/FiO₂ is not provided.

Sets the respiratory subscore to at least 3 regardless of the ratio.

Grades acute-on-chronic liver failure by counting organ failures. Provide either the PaO₂/FiO₂ or the SpO₂/FiO₂ ratio — whichever you have.

When to use
Use it in a patient admitted with acute decompensation of cirrhosis, to establish whether acute-on-chronic liver failure is present and at what grade — and then repeatedly, because the trajectory over the first three to seven days predicts outcome better than the value at diagnosis. It is the instrument that defines the syndrome under the European framework, so it determines whether a patient is described as having ACLF at all rather than simply decompensated cirrhosis. It is not a triage tool for the stable outpatient, it does not apply to acute liver failure in a previously normal liver, and it should not be used to rank transplant priority — MELD 3.0 does that. Note also that the APASL framework defines ACLF differently and would classify some of these patients otherwise.
Why use it
Because 'decompensated cirrhosis' spans a 28-day mortality range from about 2% to about 77%, and before CANONIC there was no agreed way to say which end of it a patient occupied. The CANONIC investigators built the criteria by working backwards from mortality: they identified which combinations of organ failure carried a 28-day mortality above 15% and defined acute-on-chronic liver failure as those combinations. That is why the grading has prognostic content rather than merely descriptive content, and why the syndrome is now treated as distinct from ordinary decompensation. The practical payoff is that a grade puts a number on urgency — it tells you whether this admission is a ward problem or a transplant-assessment-today problem, in a population where clinical impression consistently underestimates how fast things move.
Formula, evidence and interpretation

About the Chronic Liver Failure — Sequential Organ Failure Assessment (CLIF-SOFA)

What CLIF-SOFA is actually for is identifying organ failures, not adding points. It adapts the intensive care SOFA score to cirrhosis across six systems — liver, kidney, coagulation, circulation, brain and lungs — and the total matters far less than which of them have crossed their failure threshold. Two or more failures give ACLF grade 2 or 3; a single failure only qualifies as grade 1 if it is kidney failure, or is accompanied by creatinine 1.5–1.9 mg/dL or hepatic encephalopathy grade I–II. In the CANONIC study of 1,343 patients, 28-day mortality was 22.1% at grade 1, 32.0% at grade 2 and 76.7% at grade 3, against 1.9% with no organ failure at all.

On this page

  • Formula
  • Interpreting the result
  • Inputs
  • What it returns
  • How it is calculated
  • Facts & figures
  • Evidence
  • How it compares
  • Pearls & pitfalls
  • Critical actions
  • Why it exists
  • About the creator
  • Limitations
  • If you are the patient
  • FAQ
  • Related calculators
  • References

Formula

CLIF-SOFA = liver + kidney + coagulation + circulation + brain + lungs (each 0–4) Organ failure = liver ≥ 3, kidney ≥ 2, coagulation ≥ 3, circulation ≥ 3, brain ≥ 3, lungs ≥ 3
liver
Bilirubin in mg/dL: 0 below 1.2, 1 below 2, 2 below 6, 3 below 12, 4 at 12 or above. Failure at 3.
kidney
Creatinine in mg/dL: 0 below 1.2, 1 below 2, 2 below 3.5, 3 below 5, 4 at 5 or above. Failure at 2 — the only system whose failure threshold is a subscore of 2.
coagulation
INR: 0 below 1.1, 1 below 1.25, 2 below 1.5, 3 below 2.5, 4 at 2.5 or above. Failure at 3.
circulation
3 if on vasopressors; otherwise 0 at a mean arterial pressure of 70 mmHg or more, 1 below 70. Failure at 3, which in practice means vasopressor dependence.
brain
West Haven grade 0 to 4 used directly as the subscore. Failure at 3 — West Haven grade III, somnolence to semi-stupor.
lungs
PaO₂/FiO₂: 0 above 400, 1 above 300, 2 above 200, 3 above 100, 4 at 100 or below. Or SpO₂/FiO₂: 0 above 512, 1 above 357, 2 above 214, 3 above 89, 4 at 89 or below. Mechanical ventilation forces at least 3. Failure at 3.
  • The failure thresholds are not uniform. Five systems fail at a subscore of 3 and the kidney fails at 2, which is easy to miss and changes the grade.
  • The total is not the output that matters. A CLIF-SOFA of 10 spread across six systems with none in failure is a different patient from a CLIF-SOFA of 10 concentrated in three failing systems.
  • Vasopressor use overrides mean arterial pressure. A patient maintained at 75 mmHg on noradrenaline scores 3 and is in circulatory failure.
  • Mechanical ventilation forces the respiratory subscore to at least 3, so an intubated patient is in respiratory failure whatever their oxygenation ratio shows.
  • The SpO₂/FiO₂ thresholds are not the PaO₂/FiO₂ thresholds. They are separate cut-offs derived from the relationship between the two ratios, and using one set with the other measurement misclassifies patients.
  • Grade 1 is not simply "one organ failure". It is single kidney failure, OR a single liver, coagulation, circulatory or respiratory failure accompanied by creatinine 1.5–1.9 mg/dL and/or hepatic encephalopathy grade I–II, OR single cerebral failure with creatinine 1.5–1.9 mg/dL. A single non-kidney organ failure with normal renal and cerebral function is organ failure without ACLF.

Interpreting the result

No organ failure in a patient admitted with decompensated cirrhosis carries a 28-day mortality of about 1.9%, and that patient does not have acute-on-chronic liver failure — treat the decompensation and watch, because ACLF can declare itself over the following days. Grade 1 carries roughly 22% 28-day mortality, grade 2 about 32%, and grade 3 about 77%. The single most useful thing to know about these grades is that they are dynamic: the CLIF-C ACLF score computed at 48 hours and again at three to seven days predicts 28-day mortality significantly better than the value at diagnosis, so a grade recorded on admission is a starting point rather than a verdict. Roughly two in five patients have no precipitant identified, which is worth knowing so that failure to find one does not stop the search prematurely — infection, alcohol, variceal bleeding and drug injury account for most of the rest and all are actionable. Assess transplant candidacy early, because the practical window narrows as organs fail and a grade 3 patient who was never assessed at grade 1 has usually lost the opportunity rather than been denied it.

ScoreBandWhat it meansAction
No organ failureDecompensated cirrhosis without ACLF28-day mortality approximately 1.9% in the CANONIC cohortTreat the decompensation and its precipitant; reassess daily, since 112 of 1,343 CANONIC patients developed ACLF after enrolment
1 organ failure meeting the qualifying patternACLF grade 128-day mortality 22.1%Identify and treat the precipitant; intensive monitoring; begin transplant assessment now rather than on deterioration
2 organ failuresACLF grade 228-day mortality 32.0%Critical care input; reassess the grade at 48 hours and at 3–7 days, since trajectory outperforms the admission value
3 or more organ failuresACLF grade 328-day mortality 76.7%Intensive care and urgent transplant evaluation; where transplantation is not an option, involve palliative care alongside active treatment

Scroll the table sideways for every column.

What the CLIF-SOFA needs (6 inputs)

Total bilirubin — liver
Scored 0 below 1.2 mg/dL, 1 to 2, 2 to 6, 3 to 12, and 4 above 12. Liver failure is defined at a subscore of 3, meaning bilirubin of 12 mg/dL or above.
Creatinine — kidney
Scored 0 below 1.2 mg/dL, 1 to 2, 2 to 3.5, 3 to 5, and 4 above 5. Kidney failure is defined at a subscore of 2 — a creatinine of 2.0 mg/dL — which is a lower bar than any other system and is deliberate, because renal dysfunction in cirrhosis carries disproportionate prognostic weight.
INR — coagulation
Scored 0 below 1.1, rising through 1.25 and 1.5 to 4 at 2.5 and above. Coagulation failure is a subscore of 3, meaning an INR of 2.5 or above.
Mean arterial pressure and vasopressor use — circulation
0 at a mean arterial pressure of 70 mmHg or above, 1 below 70. Vasopressor use overrides the pressure entirely and scores 3, which is the circulatory failure threshold — so a patient with a normal pressure on noradrenaline is in circulatory failure.
Hepatic encephalopathy grade — brain
The West Haven grade entered directly as the subscore, 0 to 4. Cerebral failure is grade 3 or above. An error in West Haven grading propagates straight into the ACLF grade.
PaO₂/FiO₂ or SpO₂/FiO₂ ratio, and mechanical ventilation — lungs
Either ratio can be used; the arterial one is preferred where a blood gas is available. Mechanical ventilation sets the respiratory subscore to at least 3 regardless of the ratio, which is the respiratory failure threshold.

Units. Bilirubin and creatinine can be entered in either conventional or SI units and are converted internally. The published thresholds are in mg/dL: bilirubin failure at 12 mg/dL (205 µmol/L) and kidney failure at a creatinine of 2.0 mg/dL (177 µmol/L). The respiratory subscore has two separate threshold sets — PaO₂/FiO₂ at 400/300/200/100 and SpO₂/FiO₂ at 512/357/214/89 — and they are not interchangeable; applying the arterial cut-offs to a saturation-derived ratio will misclassify the subscore in either direction.

What it returns

CLIF-SOFA total
The sum of the six subscores. Reported for completeness, but the total is not what the ACLF definition uses and two patients with identical totals can differ by two grades.
Number of organ failures
The count of systems at or above their failure threshold, and which ones. Two or more settles the grade on its own; a single failure has to be tested against the grade 1 qualifying patterns.
ACLF grade and 28-day mortality
Grade 1, 2 or 3 with the CANONIC 28-day mortality attached: 22.1%, 32.0% and 76.7% respectively.

How it is calculated

The score is an adaptation of the intensive care SOFA score, retuned so that its thresholds reflect what the same laboratory values mean in a cirrhotic patient rather than a general critical care population. But the important methodological step in CANONIC was not the score — it was how the syndrome was defined from it. The investigators enrolled 1,343 patients hospitalised for acute decompensation of cirrhosis across 29 liver units in eight European countries, recorded organ failures by CLIF-SOFA, and then asked which patterns of failure identified a group with a 28-day mortality above 15%. Acute-on-chronic liver failure was defined as those patterns. The grading follows the same logic: mortality rises steeply with the number of failing organs, and the three grades mark that gradient. This is why the framework is empirical rather than consensus-derived, and why the renal threshold sits lower than the others — the data, not clinical opinion, put it there.

Facts & figures

Organ failure thresholds — note the renal exception
SystemSubscore defining failureWhat that means clinically
Liver≥ 3Bilirubin ≥ 12 mg/dL
Kidney≥ 2Creatinine ≥ 2.0 mg/dL — the lowest bar of the six, by design
Coagulation≥ 3INR ≥ 2.5
Circulation≥ 3Vasopressor requirement, irrespective of the achieved blood pressure
Brain≥ 3West Haven grade III or IV
Lungs≥ 3PaO₂/FiO₂ ≤ 200, SpO₂/FiO₂ ≤ 214, or mechanical ventilation

Scroll the table sideways for every column.

Reading all six as failing at 3 is the commonest error and systematically under-diagnoses ACLF, because renal dysfunction is both the most frequent organ failure in this population and the one with the lowest threshold.

CANONIC outcomes (1,343 patients, 29 units, 8 countries)
Groupn28-day mortality
ACLF at enrolment30333.9%
Developed ACLF during follow-up11229.7%
Never developed ACLF9281.9%

Scroll the table sideways for every column.

The 112 patients who developed ACLF after enrolment are the reason a single admission score is insufficient. Their mortality was close to that of patients who presented with the syndrome, and none of them would have been identified by an admission assessment alone.

Evidence

Derivation — CANONIC study, EASL-CLIF Consortium

2013 · n = 1,343

Prospective observational study of patients hospitalised for acute decompensation of cirrhosis at 29 liver units in eight European countries between February and September 2011. Diagnostic criteria for ACLF were established by identifying which patterns of organ failure, defined by CLIF-SOFA, carried a 28-day mortality above 15%.

303 patients had ACLF at enrolment (28-day mortality 33.9%), 112 developed it during follow-up (29.7%), and 928 never did (1.9%). By grade, 28-day mortality was 22.1% at grade 1, 32.0% at grade 2 and 76.7% at grade 3.

Simplification and prognostic score — CLIF-C OF and CLIF-C ACLF

2014 · n = 275

Development and validation within the CANONIC dataset of a simplified organ function score (CLIF-C OF) for diagnosing ACLF, and a prognostic score (CLIF-C ACLF) built on 275 patients with ACLF.

CLIF-C ACLF showed significantly higher predictive accuracy than MELD, MELD-Na and Child-Pugh, reducing prediction error rates by 19–28% at 28, 90, 180 and 365 days. Scores computed at 48 hours and at 3–7 and 8–15 days after diagnosis predicted 28-day mortality significantly better than at diagnosis.

Comparison against the APASL framework — Choudhury 2017

2017 · n = 1,402

1,402 patients from the APASL ACLF Research Consortium, used to compare the AARC score against CLIF-SOFA and MELD for predicting mortality in a population defined by the APASL rather than the EASL-CLIF criteria.

The AARC score achieved an AUROC of 0.80 in derivation and 0.78 in validation and was reported as superior to MELD and CLIF-SOFA in that cohort — a result that reflects the different populations the two frameworks define as much as the scores themselves.

Guideline adoption — EASL 2018

2018

EASL clinical practice guidelines for the management of patients with decompensated cirrhosis, incorporating the CANONIC definition and grading of acute-on-chronic liver failure.

Adopted the EASL-CLIF organ failure criteria and ACLF grading as the European standard, and endorsed serial reassessment rather than reliance on the admission grade.

How it compares

CLIF-SOFA vs CLIF-C OF and CLIF-C ACLF

CLIF-C OF replaced CLIF-SOFA for diagnosis and CLIF-C ACLF is the better prognostic score — CLIF-SOFA is the original instrument, not the current best one.

Within a year of CANONIC the same consortium simplified CLIF-SOFA into the CLIF-C organ failure score for diagnosing the syndrome, and derived a separate prognostic score, CLIF-C ACLF, in 275 patients with ACLF. CLIF-C ACLF showed significantly higher predictive accuracy than MELD, MELD-Na and Child-Pugh, reducing prediction error by 19–28% at 28, 90, 180 and 365 days. If the question is prognosis, CLIF-C ACLF is the instrument the evidence supports. CLIF-SOFA retains value because it is the score the syndrome was originally defined with and the one much of the subsequent literature is expressed in, so understanding it is necessary to read the field.

Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047.

CLIF-SOFA vs AARC-ACLF score (APASL)

They grade different syndromes rather than competing on the same one — APASL excludes previously decompensated patients, EASL-CLIF includes them, so the two frameworks are not scoring the same population.

This is the most consequential distinction in the ACLF literature and it is frequently glossed over. The APASL definition requires an acute hepatic insult producing jaundice and coagulopathy in a patient with chronic liver disease, and explicitly excludes those with prior decompensation; EASL-CLIF starts from acute decompensation of cirrhosis and defines the syndrome by organ failure and mortality. A patient with prior ascites who presents with renal failure has ACLF by EASL-CLIF and falls outside APASL entirely. In the APASL cohort of 1,402 patients the AARC score outperformed CLIF-SOFA with an AUROC of 0.80, which is a real finding about that population rather than evidence that one score is universally better. Use whichever framework matches your population, and say which one you used.

Open the AARC-ACLF score (APASL) calculator →Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461-471.

CLIF-SOFA vs MELD-Na

MELD-Na ranks waiting-list priority from four laboratory values; CLIF-SOFA identifies a syndrome across six organ systems and predicts short-term mortality better in that population.

MELD-Na was fitted to three-month mortality in a waiting-list population and has no representation of circulatory or respiratory failure, encephalopathy or vasopressor dependence. In acute-on-chronic liver failure those are precisely the variables driving outcome, which is why the CLIF-C ACLF score outperformed MELD and MELD-Na in the CANONIC dataset. The two do different jobs: MELD-Na remains the allocation instrument and should still be calculated, while CLIF-SOFA determines whether the patient is in a syndrome whose mortality MELD-Na will understate.

Open the MELD-Na calculator →

CLIF-SOFA vs Child-Pugh score

Child-Pugh grades chronic hepatic function and is not built for an acute deterioration — CLIF-C ACLF reduced prediction error by 19–28% against it in ACLF.

Child-Pugh describes where a patient sits in the natural history of their cirrhosis, using variables that move slowly, and it has no way to represent renal, circulatory or respiratory failure. A Child-Pugh B patient can be in grade 3 ACLF with a 77% 28-day mortality, and the Child-Pugh grade will not have changed. It remains useful as the baseline against which an acute deterioration is measured, and it is still the standard in some non-transplant contexts, but it should not be the instrument on which acute prognosis rests in this setting.

Open the Child-Pugh score calculator →

Pearls & pitfalls

  • The kidney fails at a subscore of 2, not 3. Applying a uniform threshold of 3 across all six systems under-diagnoses ACLF, and it does so in the system where failure is both commonest and most prognostically loaded.
  • One organ failure does not automatically mean grade 1 ACLF. A single liver, coagulation, circulatory or respiratory failure only qualifies when accompanied by creatinine 1.5–1.9 mg/dL and/or hepatic encephalopathy grade I–II; single kidney failure qualifies on its own; single cerebral failure needs creatinine 1.5–1.9. A patient with one non-renal organ failure and normal renal and cerebral function has organ failure without ACLF.
  • Renal dysfunction for that qualifying rule is creatinine 1.5–1.9 mg/dL specifically, which is narrower than the kidney subscore of 1 (1.2–1.99). Reading the subscore instead of the creatinine wrongly admits a creatinine of 1.3.
  • The total is close to meaningless on its own. Report the number of organ failures and the grade; a CLIF-SOFA of 12 tells the next clinician nothing about which organs are failing.
  • Vasopressor use is circulatory failure. Do not score circulation from the achieved blood pressure in a patient on noradrenaline — the pressure is a treatment effect.
  • Mechanical ventilation is respiratory failure regardless of oxygenation. An intubated patient with a PaO₂/FiO₂ of 350 still scores 3.
  • The SpO₂/FiO₂ cut-offs differ from the PaO₂/FiO₂ cut-offs. Using 400/300/200/100 with a saturation-derived ratio will misclassify the respiratory subscore.
  • An error in West Haven grading becomes an error in ACLF grade, because the encephalopathy grade is used directly as the cerebral subscore.
  • Regrade daily. Trajectory at 48 hours and at three to seven days predicts 28-day mortality better than the admission value, and 112 of the 1,343 CANONIC patients developed ACLF only after enrolment.
  • About 40% have no identified precipitant. That is a known feature of the syndrome, not evidence that the search was adequate — check for infection, alcohol, bleeding and drugs explicitly.
  • APASL defines ACLF differently and excludes previously decompensated patients. A patient can have ACLF by EASL-CLIF and not by APASL, and the literature does not always say which framework it is using.

Critical actions

  • Count organ failures using the correct per-system thresholds, remembering that the renal threshold is a creatinine of 2.0 mg/dL.
  • Search actively for a precipitant: diagnostic paracentesis where ascites is present, blood and urine cultures, a review of alcohol intake, assessment for variceal bleeding, and a drug history including herbal and over-the-counter agents.
  • Recalculate at 48 hours and again at three to seven days, and record the trend — the trajectory carries more prognostic information than the admission grade.
  • Assess transplant candidacy at grade 1, not at grade 3. The assessment takes time the patient may not have later.
  • Escalate the care setting to match the grade rather than the current observations, since deterioration in this syndrome is rapid and often not heralded.
  • Grade encephalopathy carefully with West Haven criteria, since that grade enters the score directly.
  • State which framework you are using — EASL-CLIF or APASL — when documenting ACLF, because the two define different populations.
  • Where transplantation is not feasible at grade 3, involve palliative care alongside active treatment rather than sequentially.

Why this score exists

The CANONIC investigators set out to answer a question that sounds definitional but is empirical: does acute-on-chronic liver failure exist as a distinct entity, or is it just severe decompensation. Their method was to refuse to define it by consensus. They enrolled consecutively, recorded organ failures prospectively, and let mortality draw the boundary — the 15% threshold at 28 days is the line they chose, and the combinations of organ failure that crossed it became the definition. That is why the resulting criteria contain an asymmetry no committee would have designed: the kidney fails at a lower subscore than every other system, because in this population that is what the data showed. The same logic explains the emphasis on serial assessment that the follow-up work made explicit — if the syndrome is defined by mortality risk, and risk changes over the first week, then a single measurement was never going to be the right unit of observation.

About the creator

  • Richard Moreau

    First author, CANONIC study

    Led the CANONIC study that defined acute-on-chronic liver failure and its grading from CLIF-SOFA organ failures.

  • Rajiv Jalan

    Co-author of CANONIC; first author of the CLIF-C OF and CLIF-C ACLF development

    Developed the simplified CLIF-C OF score for diagnosis and the CLIF-C ACLF prognostic score, and established that serial assessment outperforms the value at diagnosis.

  • Vicente Arroyo

    Senior author, CANONIC; EASL-CLIF Consortium

    Senior author of the CANONIC study and a principal architect of the EASL-CLIF Consortium's work on the syndrome.

Limitations

  • The grade 1 definition is intricate — three qualifying patterns rather than a count — and is frequently applied as "any single organ failure" in practice and in secondary sources, which over-diagnoses ACLF in patients with isolated non-renal organ failure.
  • CLIF-SOFA has been superseded for diagnosis by CLIF-C OF and for prognosis by CLIF-C ACLF, both from the same consortium.
  • Derived entirely in European liver units, where alcohol-related cirrhosis predominates. Performance differs in populations dominated by hepatitis B, which is part of why the APASL framework exists.
  • The grade at diagnosis is the weakest measurement available — the same score at 48 hours and at three to seven days predicts 28-day mortality significantly better.
  • Requires arterial blood gas or oxygen saturation data and a mean arterial pressure, so it cannot always be completed at the point of admission.
  • The cerebral subscore inherits the reproducibility problems of West Haven grading, which is weakest at the lower grades.
  • Says nothing about the precipitant, and about 40% of patients have none identified — the score describes severity, not what to treat.
  • Not an allocation instrument, and its use to argue transplant priority conflates prognosis with the separate policy question of how organs are distributed.
  • The vasopressor and ventilation overrides mean the score partly measures treatment received, so it is sensitive to local thresholds for escalating support.

If you are the patient

CLIF-SOFA is a way of measuring how many of the body's major systems are failing in someone with long-standing liver disease who has become acutely unwell. Six are checked: the liver itself, the kidneys, blood clotting, the circulation, the brain, and the lungs. What matters most is not the total but how many of those six have crossed into failure, because that count identifies a condition called acute-on-chronic liver failure and indicates how urgent the situation is. In the large European study that defined it, people admitted with liver decompensation but no organ failure had around a 2% risk of dying within a month, while those with three or more failing organs had around a 77% risk. Two things follow from that, and both are hopeful rather than otherwise. First, the score is repeated over the following days rather than being decided on admission, because it can improve as well as worsen, and how it changes over the first week says more than the first reading. Second, there is almost always a trigger — an infection, a bleed, alcohol, or a new medication — and finding and treating it is the main thing that changes the outcome. This is also the point at which the team will consider whether a liver transplant is an option, and they will do that assessment early rather than waiting, because it takes time to arrange.

Frequently asked questions

What is CLIF-SOFA?#

An adaptation of the intensive care SOFA score to cirrhosis, scoring six organ systems — liver, kidney, coagulation, circulation, brain and lungs — from 0 to 4 each. Its purpose is to identify organ failures, and the count of failing organs defines acute-on-chronic liver failure and its grade under the EASL-CLIF framework established by the CANONIC study.

What are the ACLF grades and their mortality?#

In the CANONIC study of 1,343 patients, 28-day mortality was 22.1% at grade 1, 32.0% at grade 2 and 76.7% at grade 3, against 1.9% in patients admitted with decompensated cirrhosis who never developed organ failure. The grades correspond to one, two, and three or more organ failures respectively, with the important detail that the published grade 1 definition requires either kidney failure or another single organ failure accompanied by renal or cerebral dysfunction.

What counts as an organ failure in CLIF-SOFA?#

Liver at a bilirubin of 12 mg/dL or above, coagulation at an INR of 2.5 or above, circulation at vasopressor requirement, brain at West Haven grade III or IV, and lungs at a PaO₂/FiO₂ of 200 or below, an SpO₂/FiO₂ of 214 or below, or mechanical ventilation. The kidney is the exception: failure is defined at a creatinine of 2.0 mg/dL, a subscore of 2 rather than 3.

Why is the kidney threshold lower than the others?#

Because the criteria were derived empirically rather than by consensus. The CANONIC investigators identified which patterns of organ failure carried a 28-day mortality above 15%, and renal dysfunction crossed that line at a lower level of derangement than the other systems. It reflects how much prognostic weight kidney function carries in cirrhosis, and it is why applying a uniform threshold of 3 across all six systems under-diagnoses the syndrome.

Should CLIF-SOFA be repeated or calculated once?#

Repeated. The follow-up work from the same consortium showed that scores computed at 48 hours and at three to seven and eight to fifteen days after diagnosis predicted 28-day mortality significantly better than the value at diagnosis. In CANONIC itself, 112 of 1,343 patients developed ACLF only after enrolment, and their mortality approached that of patients who presented with it — none would have been identified by an admission assessment alone.

What is the difference between CLIF-SOFA and CLIF-C OF?#

CLIF-C OF is a simplified organ function score developed by the same consortium a year after CANONIC, and it replaced CLIF-SOFA for diagnosing ACLF. A separate score, CLIF-C ACLF, was derived for prognosis and outperformed MELD, MELD-Na and Child-Pugh, reducing prediction error by 19–28%. CLIF-SOFA remains worth understanding because it is the instrument the syndrome was originally defined with and the one much of the literature uses.

How does EASL-CLIF differ from the APASL definition of ACLF?#

Fundamentally. EASL-CLIF starts from acute decompensation of cirrhosis and defines the syndrome by organ failure and 28-day mortality, including patients with prior decompensation. APASL requires an acute hepatic insult causing jaundice and coagulopathy and explicitly excludes previously decompensated patients. A patient with established ascites who presents in renal failure has ACLF by EASL-CLIF and falls outside APASL altogether, so the two frameworks describe overlapping but genuinely different populations.

Does CLIF-SOFA determine transplant priority?#

No — allocation runs on MELD 3.0 or an equivalent national model, and CLIF-SOFA has no formal role in it. What the grade should drive is the timing of assessment: candidacy is best evaluated at grade 1, because the assessment takes time and the practical window narrows as further organs fail. A grade 3 patient who was never assessed earlier has usually run out of time rather than been declined.

How often is a precipitant found in ACLF?#

In roughly 60% of cases. About two in five patients have no identifiable trigger, which is a recognised feature of the syndrome rather than a sign of an incomplete work-up — though it should not stop the search. Bacterial infection, alcohol, variceal bleeding and drug-induced injury account for most of those that are identified, and all are actionable.

Related calculators

  • SAAG — Serum-ascites albumin gradient — cause of ascites
  • AARC-ACLF — Acute-on-chronic liver failure grade
  • CLIF-C ACLF — Mortality prediction in acute-on-chronic liver failure
  • West Haven Criteria — Hepatic encephalopathy grading
  • Child-Pugh Score — Assesses the prognosis of chronic liver disease, mainly cirrhosis
  • MELD-Na — Assesses the severity of chronic liver disease
  • MELD 3.0 — Updated MELD — sex-inclusive formula
  • King's College Criteria — Transplant criteria in acute liver failure
  • Lille Model — Steroid response at day 7 in alcoholic hepatitis
  • RUCAM — Causality in drug- and herb-induced liver injury

References

Original / primary reference

  1. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437 (CANONIC study).

Validation and evidence

  1. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gines P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047 (CLIF-C OF and CLIF-C ACLF).
  2. Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461-471.

Clinical practice guidelines

  1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.

Last updated July 30, 2026. Clinical knowledge base written and curated by GastroAGI Team from primary medical literature.

Written from primary literature and not yet independently clinically reviewed.

For use by qualified healthcare professionals. This calculator supports clinical judgement and does not replace it.